Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.41 is 47% above its 5-year average of -4.56, near the high end of its 5-year range (-6.38–-1.81).
48.28% above its 12-month average of -4.66.
Reported quarterly EPS; no daily interpolation. Q3 FY2026 (2026-06-30): -0.67.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 34 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T14:41:44.616Z. Historical observations retain their original dates. Historical series through 2020-11-25.
EARNINGS PER SHARE (EPS)
-2.41
EARNINGS PER SHARE (EPS) AVG TTM
-4.66
EARNINGS PER SHARE (EPS) AVG 3Y
-5.40
EARNINGS PER SHARE (EPS) AVG 5Y
-4.56
EARNINGS PER SHARE (EPS) AVG 10Y
-1.38
EARNINGS PER SHARE (EPS) AVG 15Y
-0.25
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+48.28%
CURRENT VS 3Y AVG
+55.39%
CURRENT VS 5Y AVG
+47.11%
CURRENT VS 10Y AVG
-74.52%
CURRENT VS 15Y AVG
-856.09%
CURRENT VS 20Y AVG
N/A
Enanta Pharmaceuticals, Inc.
Market Cap
$349.23M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$347.70M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.30
3Y Avg
-1.38
5Y Avg
-1.95
Market Cap
$354.19M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$352.93M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
Market Cap
$342.13M
Earnings Per Share (EPS)
-3.31
TTM Avg
-3.43
3Y Avg
-2.65
5Y Avg
-2.61
Market Cap
$355.99M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.39
3Y Avg
-1.39
5Y Avg
-0.93
Market Cap
$332.73M
Earnings Per Share (EPS)
-1.18
TTM Avg
-0.80
3Y Avg
-0.80
5Y Avg
-0.72
Market Cap
$331.68M
Earnings Per Share (EPS)
2.65
TTM Avg
-5.30
3Y Avg
-10.00
5Y Avg
-10.52
Market Cap
$370.48M
Earnings Per Share (EPS)
-0.50
TTM Avg
-5.17
3Y Avg
-17.19
5Y Avg
-12.52
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enanta Pharmaceuticals, Inc. (ENTA) | $349.23M | -2.41 | -4.66 | -5.40 | -4.56 |
| Opus Genetics, Inc. (IRD)vs › | $347.70M | N/A | -1.30 | -1.38 | -1.95 |
| Embecta Corp. (EMBC)vs › | $354.19M | 1.48 | 1.49 | 2.03 | 3.82 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $352.93M | -0.14 | -0.19 | -0.48 | -0.56 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $342.13M | -3.31 | -3.43 | -2.65 | -2.61 |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $355.99M | -0.99 | -1.39 | -1.39 | -0.93 |
| ClearPoint Neuro, Inc. (CLPT)vs › | $332.73M | -1.18 | -0.80 | -0.80 | -0.72 |
| Agenus Inc. (AGEN)vs › | $331.68M | 2.65 | -5.30 | -10.00 | -10.52 |
| Canopy Growth Corporation (CGC)vs › | $370.48M | -0.50 | -5.17 | -17.19 | -12.52 |
| Kyverna Therapeutics, Inc. (KYTX)vs › | $376.93M | -2.94 | -3.49 | -2.70 | -2.28 |
Trailing EPS (TTM)
$-2.41
Forward EPS (Est.)
$-2.20
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-09-30 | -3.84 |
| 2024-09-30 | -5.48 |
| 2023-09-30 | -6.38 |
| 2022-09-30 | -5.91 |
| 2021-09-30 | -3.92 |
| 2020-09-30 | -1.81 |
| 2019-09-30 | 2.37 |
| 2018-09-30 | 3.48 |
| 2017-09-30 | 0.93 |
| 2016-09-30 | 1.14 |
| 2015-09-30 | 4.23 |
| 2014-09-30 | 1.88 |
| 2013-09-30 | -0.67 |
| 2012-09-30 | 8.11 |
| 2011-09-30 | 1.82 |
| 2010-09-30 | 0.02 |
(FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown Quote observation: 2026-10-06T14:41:44.616Z. Historical observations retain their original dates. Historical series through 2020-11-25.
